The assessment of the therapeutic effectiveness of IRS-19 in allergic children with recurrent or chronic respiratory infections.
The subject of the clinical-laboratory examinations was a group of 36 children aged 1 4/12 - 17 years with recurrent upper (94%) and lower (63%) airway infections, whose condition did not improve after antibiotic therapy, elimination diet and anti-histaminic treatment. In 83% of the examined patients respiratory tract symptoms co-existed with skin (61%), gastrointestinal tract (44%) and OUN (16%) diseases. 75% of examined children, with humoral and/or cellular response disorders, were given an IRS-19 vaccine, which resulted in the regression of the respiratory tract symptoms in 78% of patients. Due to side-effects in the form of high temperature, the treatment was terminated in 14% of children. The obtained therapeutic effects and convenience of administration of the vaccine, justify IRS-19 treatment in children with recurrent lower and upper airway infections, after complex immunological examination.